相关实验视频

Updated: Jan 9, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

基于实验性耐药细胞系和临床患者的肺腺癌的预后模型

Junnan Li¹, Jiasheng Zhang², Xinyang Zhang¹

¹Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Pharmacy, Health Science Center, Hunan Normal University, Changsha, China.

Frontiers in molecular biosciences

|December 8, 2025

概括

一个新的3基因风险评分预测肺腺癌患者的生存率和对EGFR-TKI的耐药性. 该模型将体外耐药性与免疫微环境数据相结合,用于个性化治疗选择.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

皮肤上生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 已在肺腺癌 (LUAD) 治疗中取得了进展.
对EGFR-TKIs的治疗耐药性仍然是LUAD管理中的重大临床挑战.

研究的目的:

开发一种预后模型,将体外耐药性机制与免疫微环境特征相结合.
预测患者的结果,并指导LUAD的治疗策略.

主要方法:

确立了EGFR-TKI耐药HCC827细胞系,并进行了RNA测序.
使用LASSO-COX回归与LUAD数据构建了一个预后风险评分模型.
通过基因组变异分析和单细胞RNA-seq. 分析了免疫透.

主要成果:

开发了一个3基因风险评分 (PPP1R3G,CREG2,LYPD3),预测了低生存率和对EGFR-TKI的耐药性.
在高风险患者中确定了免疫抑制的微环境,包括丰富的调节性T细胞.
创建了一个整合RiskScore和临床因素进行个性化预后 (C指数=0.7) 的名图.

结论:

开发的模型将体外耐药机制与临床免疫景观联系起来.
这种工具可以对针对性疗法,免疫疗法或组合策略的LUAD患者进行分层.

关键词:

对于EGFR-TKIs的耐药性,我们有所作为.免疫微观环境免疫微环境肺癌是一种肺癌.预后预测预测预测单细胞RNA-seq (scRNA-seq) 是一个单细胞RNA-seq.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频